PTC guided individualized treatment

PreclinicalSmall molecule

PTC guided individualized treatment is one of 24 small molecule programs targeting Mesothelioma. It is currently in Preclinical.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

MesotheliomaActive, not recruiting

MesotheliomaPreclinical

Active, not recruiting

Competition

Competitive Landscape

26 competitors in Mesothelioma

#DrugCompanyPhaseTrials

Lynparza

Afinitor

Iressa

Nexavar

Zometa

Mitosol

Photofrin

PPinnacle Biologics Inc.

Yondelis

Beleodaq

AAcrotech Biopharma Inc.

Approved

—10

Zolinza

CCidara Therapeutics Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)

Approved

—

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q4 2031

N/ARecruiting

Mesothelioma

NCT07330271

Clinical

Trials by Indication[1]

Mesothelioma1 trial

PTC-Guided Therapy for Peritoneal Mesothelioma

Recruiting·—·N/A·NCT07330271·347 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for PTC guided individualized treatment. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — PTC guided individualized treatment compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for PTC guided individualized treatment. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Beijing Tsinghua Chang Gung Hospital company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Preclinical[1]
Company: BBeijing Tsinghua Chang Gung Hospital

PTC guided individualized treatment

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q4 2031

Trials by Indication[1]

Mesothelioma1 trial

References

Drug Info

Quick Facts

Related News